As­traZeneca sells off heart fail­ure and hy­per­ten­sion drugs to Chep­lapharm for $400M

Out with the old and in with the new: As­traZeneca is sell­ing off two heart fail­ure and hy­per­ten­sion drugs to Ger­many-based Chep­lapharm, bag­ging $400 mil­lion and mak­ing way for de­vel­op­ment in oth­er ar­eas.

Chep­lapharm paid $200 mil­lion for the Eu­ro­pean rights to At­a­cand (can­desar­tan cilex­etil) and At­a­cand Plus (can­desar­tan cilex­etil and hy­drochloroth­iazide) back in 2018. They’re now dou­bling that amount for com­mer­cial con­trol in more than 70 coun­tries.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.